Ciprofloxacin: a novel therapeutic agent for iron overload? (2009)
Mitra Elmi,Parvaneh Rahimi-Moghaddam,Khosrou Abdi,
Mehdi Shafiee-Ardestani,Massoud Mahmoudian
Abstract
Objective:
Major thalassemia is one of the hematological diseases requiring
multiple blood transfusions, which results in iron overload in the
liver, heart and other organs.
Current iron chelation therapy consists of intravenous (IV)
deferoxamine and oral deferasirox and deferiprone.
Although these chelators are effective, many side effects are
reported.
In the present study, the iron-chelating effect of ciprofloxacin with
good oral absorption was investigated.
Material and Methods:
Thirty male albino Wistar rats were used for the study. Ciprofloxacin
(7 or 14 mg/kg per day) was administered simultaneously with iron
(0.03 g/kg per day) or after one-month administration of iron.
Ciprofloxacin effect on iron absorption in the liver and heart was
studied carefully using atomic absorption.
Results:
A significant decrease in the liver and heart iron following the
ciprofloxacin (14 mg/kg per day) administration was observed, when
compared with the control group.
This ciprofloxacin-induced tissue iron depletion was more pronounced
when it was administered simultaneously with iron, when it was administered
for a longer duration (2 months rather than 1 month) and when it was given
in higher doses (14 mg/kg per day).
Conclusion:
Administration of ciprofloxacin may help to decrease the burden of
parenteral administration, thereby improving compliance and also the life
expectancy of thalassemic patients.
Publication details
Download
http://www.journalagent.com/z4/downl...g&un=TJH-04796http://www.doaj.org/doaj?func=openur...e=03&spage=114Publisher Aves Yayincilik
Repository DOAJ-Articles (Sweden)
Keywords Thalassemia, iron overload, ciprofloxacin, atomic absorption,
chelator
-----------------------
http://en.wikipedia.org/wiki/CiprofloxacinCiprofloxacin is marketed worldwide with over three hundred different
brand names. In the United States, Canada and the UK, it is marketed
as Ciloxan, Cipro, Cipro XR, Cipro XL Ciproxin and, most recently,
Proquin. In Mexico it is available over the counter and marketed under
the names Ciproflox or Ciprofloxacino. In Ecuador it is available and
marketed under the name Cidrax. In Nigeria it is sold as Ciprotab
while in Bangladesh it is marketed as Tablets and Microcapsules for
Suspension by numerous companies, one of which is by Edruc Limited as
Cipron. Additionally, ciprofloxacin is available as a generic drug
under a variety of different brand names and is also available for
limited use in veterinary medicine.
Ciprofloxacin was first patented in 1983 by Bayer A.G. and
subsequently approved by the United States Food and Drug
Administration (FDA) in 1987.